AR122933A1 - Métodos para tratar la enfermedad cardiovascular - Google Patents

Métodos para tratar la enfermedad cardiovascular

Info

Publication number
AR122933A1
AR122933A1 ARP210101936A ARP210101936A AR122933A1 AR 122933 A1 AR122933 A1 AR 122933A1 AR P210101936 A ARP210101936 A AR P210101936A AR P210101936 A ARP210101936 A AR P210101936A AR 122933 A1 AR122933 A1 AR 122933A1
Authority
AR
Argentina
Prior art keywords
cardiovascular disease
methods
treat cardiovascular
disease
ziltivekimab
Prior art date
Application number
ARP210101936A
Other languages
English (en)
Inventor
Michael H Davidson
Rahul Kakkar
Madhav N Devalaraja
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR122933A1 publication Critical patent/AR122933A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

La descripción proporciona métodos para tratar la enfermedad cardiovascular, incluidos pacientes con enfermedad cardiovascular aterosclerótica y/o enfermedad renal crónica. El método comprende la administración de una cantidad terapéuticamente eficaz de ziltivekimab.
ARP210101936A 2020-07-10 2021-07-08 Métodos para tratar la enfermedad cardiovascular AR122933A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063050441P 2020-07-10 2020-07-10

Publications (1)

Publication Number Publication Date
AR122933A1 true AR122933A1 (es) 2022-10-19

Family

ID=77126785

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101936A AR122933A1 (es) 2020-07-10 2021-07-08 Métodos para tratar la enfermedad cardiovascular

Country Status (5)

Country Link
US (1) US20230287105A1 (es)
EP (2) EP4309734A1 (es)
AR (1) AR122933A1 (es)
TW (1) TW202216763A (es)
WO (1) WO2022008702A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
PL3415535T3 (pl) 2005-05-20 2021-06-14 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
EP2297202B1 (en) 2008-05-13 2016-01-13 NovImmune SA Anti-il-6/il-6r antibodies and methods of use thereof
SG172354A1 (en) 2009-01-29 2011-07-28 Medimmune Llc Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
MX2018000778A (es) 2015-07-31 2018-08-15 Medimmune Ltd Metodos para tratar trastornos mediados por hepcidinas.
AU2018214554C1 (en) 2017-02-01 2022-12-15 Novo Nordisk A/S Treatment of diuretic resistance
CA3087699A1 (en) * 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression

Also Published As

Publication number Publication date
EP4178673A1 (en) 2023-05-17
TW202216763A (zh) 2022-05-01
EP4309734A1 (en) 2024-01-24
US20230287105A1 (en) 2023-09-14
WO2022008702A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
AR099707A1 (es) Composiciones y métodos para tratar trastornos renales
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
EA202091846A1 (ru) Соединения с активностью, индуцирующей ферроптоз, и способы их применения
AR083957A1 (es) Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
PA8849001A1 (es) Anticuerpos de c-met
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
PE20211196A1 (es) Metodos para tratar inflamacion mediada por il-6 sin inmunosupresion
AR119158A1 (es) Tratamientos de angioedema hereditario
PE20211065A1 (es) Metodo para tratar la epilepsia
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
WO2018102687A3 (en) Combination therapy for treating cancer
AR119159A1 (es) Tratamientos de angioedema
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2022012557A (es) Metodos de tratamiento de la enfermedad renal diabetica.
ECSP22066085A (es) ANTICUERPOS CONTRA LA INTEGRINA alfaVß8 PARA SU USO EN EL TRATAMIENTO DE LA ENFERMEDAD RENAL
BR112017009668A2 (pt) métodos de tratamento da ckd utilizando predictores de retenção de fluidos
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
AR122933A1 (es) Métodos para tratar la enfermedad cardiovascular
EA201291122A1 (ru) Средство для профилактики и лечения заболеваний, которые сопровождаются болью в органах мочеиспускания
DOP2017000069A (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
EA202091143A1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина
CL2021003303A1 (es) Tratamiento para sinucleinopatías.

Legal Events

Date Code Title Description
FB Suspension of granting procedure